A double blind, placebo-controlled, randomized clinical trial that breast milk derived-BNR17 mitigated diarrhea-dominant irritable bowel syndrome.
J Clin Biochem Nutr. 2018 Mar ;62(2):179-186. Epub 2018 Jan 11. PMID: 29610559
Suk Pyo Shin
The exact pathogenesis of diarrhea-dominant irritable bowel syndrome (IBS) is not known, but the abnormal microbiota of the gastrointestinal tract is considered to be one of the important contributing factors as in other gastrointestinal diseases such as inflammatory bowel disease, antibiotic-associated diarrhea, and colorectal cancer as well as systemic diseases. Though diverse trials of probiotics had been continued in the treatment of diarrhea-IBS, only a few proved by randomized clinical trial. To prove the efficacy ofBNR17 isolated from breast milk in patients with diarrhea-IBS, prospective, randomized, placebo controlled clinical trial was done including health related-quality of life analysis, colon transit time, and the changes of fecal microbiota. BNR17 significantly improved the symptoms of diarrhea compared to control group. Health related-QOL analysis showed significant improvement of abdominal pain, distension, disturbed daily life, and mean defecation frequency with BNR17. On comparative CTT before and after BNR17, 6 out of 24 subjects showed significant correction of rapid colon transit pattern, while only 2 out of 24 in placebo (<0.01). Upon fecal microbiota analysis, BNR17 significantly increased,,,and. Conclusively,BNR17 can be a potential probiotics to ameliorate diarrhea-IBS.